NEW YORK (GenomeWeb News) — CXR Biosciences has licensed Rosetta Biosoftware’s Resolver system, the companies said today.
 
CXR, a Dundee, Scotland-based drug developer, said it will use the software to determine the toxicological profiles of early-stage compounds in drug -toxicity studies.
 
Financial terms of the deal were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.